Rahul Bhargava: Multiple Myeloma – the Poster Child of Innovation
Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care, posted on LinkedIn:
”Modern medicine – hope for all
Multiple Myeloma – the Poster Child of Innovation”
Multiple Myeloma truly stands as the poster boy of innovation and progress in modern hematology.
Every passing year brings a new wave of hope -breakthrough drugs, smarter combinations, and longer survival for patients once considered refractory.
We recently witnessed the remarkable impact of one such therapy in a 6th-line refractory patient post Car T cell -a reminder that science, perseverance, and timely access can turn despair into possibility.
We are living in extraordinary times where innovation is rewriting survival curves.
All we need is the means and momentum to ensure every patient benefits.
That’s why we can’t afford relapse -not in science, not in spirit.
God bless the progress, the patients, and the people behind this revolution.
Great work Heme Team
Center of excellence for myeloma and lymphoma FMRI gurugram
Anusha S., Nikhil M Kumar, Yashpal Singh Rawat, Rachit Agrawal, Devyani Surange, Aastha Gupta, Dr. Neha Rastogi Panda.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH